These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23210803)

  • 1. Role of defibrillation threshold testing in the contemporary defibrillator patient population.
    Vischer AS; Sticherling C; Kühne MS; Osswald S; Schaer BA
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):437-41. PubMed ID: 23210803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation.
    Leong-Sit P; Gula LJ; Diamantouros P; Krahn AD; Skanes AC; Yee R; Klein GJ
    Am Heart J; 2006 Dec; 152(6):1104-8. PubMed ID: 17161062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Swiatecka G
    Kardiol Pol; 2005 Apr; 62(4):317-28; discussion 329-31. PubMed ID: 15928737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated vulnerability testing identifies patients with inadequate defibrillation safety margin.
    Birgersdotter-Green U; Ruetz LL; Anand K; Monir G; Abeyratne AI; Bailey JR; Shorofsky SR; Hsia HH; Friedman PA
    Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1073-80. PubMed ID: 23051838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of successful defibrillation threshold test during CRT-D implantation.
    Przybylski A; Oreziak A; Lewandowski Z; Hasiec A; Orczykowski M; Walczak F
    Kardiol Pol; 2010 May; 68(5):512-8. PubMed ID: 20491010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?
    Russo AM; Sauer W; Gerstenfeld EP; Hsia HH; Lin D; Cooper JM; Dixit S; Verdino RJ; Nayak HM; Callans DJ; Patel V; Marchlinski FE
    Heart Rhythm; 2005 May; 2(5):456-61. PubMed ID: 15840466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Semprini L; Palano F; Santini D; Musumeci B; Santolamazza C; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2017 Jan; 28(1):103-108. PubMed ID: 27862589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Efficacy and Necessity of Routine Defibrillation Threshold Testing in Patients Undergoing Implantable Cardioverter-Defibrillator (ICD) Implantation.
    Ashino S; Nakai T; Sonoda K; Sasaki N; Kurokawa S; Ikeya Y; Okumura Y; Ohkubo K; Kunimoto S; Watanabe I; Hirayama A
    Int Heart J; 2015; 56(6):618-21. PubMed ID: 26549282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
    Curtis AB
    J Am Coll Cardiol; 2008 Aug; 52(7):557-8. PubMed ID: 18687250
    [No Abstract]   [Full Text] [Related]  

  • 15. T wave oversensing and low percentage of biventricular pacing in cardiac resynchronization therapy.
    Lezcano AO; Aracama JM; Ayestaran VU; Urra FG
    Cardiol J; 2009; 16(6):580-1. PubMed ID: 19950098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrillation threshold testing: is it necessary during implantable cardioverter-defibrillator implantation?
    Liu QM; Bai ZL; Liu ZJ; Li XP; Zhou SH
    Med Hypotheses; 2009 Feb; 72(2):147-9. PubMed ID: 18980811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Blatt JA; Poole JE; Johnson GW; Callans DJ; Raitt MH; Reddy RK; Marchlinski FE; Yee R; Guarnieri T; Talajic M; Wilber DJ; Anderson J; Chung K; Wong WS; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Aug; 52(7):551-6. PubMed ID: 18687249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C; Atienza F; Strasberg B; Arenal Á; Codner P; González-Torrecilla E; Datino T; Percal T; Almendral J; Ortiz M; Martins R; Martinez-Alzamora N; Fernandez Aviles F
    Cardiol J; 2015; 22(3):253-9. PubMed ID: 25179316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of implantable cardioverter defibrillator avoiding routine defibrillation threshold testing].
    Liu Q; Zhou S; Qi S; Zeng G; Ma X; Huang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 34(11):1132-5. PubMed ID: 19952404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.